Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAVIA: EYP-1901 in NPDR
NCT05383209Phase 2Completed
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorolanib in diabetic retinopathy (DR), sponsored by EyePoint Pharmaceuticals. Started Sep 2022; status: completed.
02
Drugs
vorolanib
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05383209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383209.